Standardized assays to monitor drug sensitivity in hematologic cancers

Area of Science:

• Hematology
• Cancer Biology
• Pharmacology

Background:

• Drug sensitivity testing precisely measures cancer cell responses to various drugs.
• Technological advancements enhance the clinical relevance of drug screening for hematologic cancers.
• Primary cancer cells, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), require specific culture conditions for accurate ex vivo testing.

Purpose of the Study:

• To present optimized and validated protocols for culturing and drug screening of primary cells from acute myeloid leukemia (AML), CLL, and MM patients.
• To provide a generic protocol for cell line models.
• To discuss drug library designs, reproducibility, and quality control measures.

Main Methods:

• Development and validation of unique microenvironmental stimuli for culturing primary AML, CLL, and MM cells.
• Implementation of drug sensitivity assays to measure cell viability.
• Establishment of quality control measures and discussion of drug library design.

Main Results:

• Optimized and validated protocols for culturing and drug screening of primary AML, CLL, and MM cells are presented.
• A generic protocol for cell line models was developed.
• Considerations for drug library design, reproducibility, and quality control were discussed.

Conclusions:

• The presented protocols can serve as community guidelines for standardizing drug sensitivity assays in hematologic cancers.
• These assays offer real-time insights into tumor biology, treatment resistance, and sensitivity.
• The findings aim to guide clinical decision-making for improved patient care.